Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
Open Access
- 8 May 2023
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 24 (1) , 1-7
Abstract
Background: Tacrolimus trough levels (C0) are used in most transplant centres for therapeutic drug monitoring (TDM) of tacrolimus (Tac). The target range of Tac C0 has been remarkably changed, with a target as low as 3–7 ng/ml in the 2009 European consensus conference and a target of 4–12 ng/ml (preferably to 7–12 ng/ml) following the second consensus report in 2019. Our aim was to investigate whether reaching early Tac therapeutic targets and maintaining time in the therapeutic range (TTR) according to the new recommendations may be necessary for preventing acute rejection (AR) during the first month after transplantation. Methods: A retrospective study including 160 adult renal transplant patients (113 men and 47 women) with a median age of 36.3 (20–44) years was conducted between January 2018 and December 2019 at 103 Military Hospital (Vietnam). Tac trough levels were recorded in the first month, and episodes of AR were confirmed by kidney biopsy. Tac TTR was calculated as the percentage of time within the target range of 7–12 ng/ml, according to the 2019 second consensus report. Multivariate Cox analysis was performed to identify the correlation between the Tac target range and TTR with AR. Results: In the first month after RT, 14 (8.8%) patients experienced AR. There was a significant difference in the incidence of AR between the Tac level groups of < 4, 4–7 and > 7 ng/ml (p = 0.0096). In the multivariate Cox analysis, after adjusting for related factors, a mean Tac level > 7 ng/ml was associated with an 86% decreased risk of AR compared with that of 4–7 ng/ml in the first month (HR, 0.14; 95% CI, 0.03–0.66; p = 0.0131). Every 10% increase in TTR was associated with a 28% lower risk of AR (HR, 0.72; 95% CI, 0.55–0.94; p = 0.014). Conclusion: Gaining and maintaining Tac C0 according to the 2019 second consensus report might reduce the risk of AR in the first month following transplantation.Keywords
This publication has 21 references indexed in Scilit:
- Antibody-mediated vascular rejection of kidney allografts: a population-based studyThe Lancet, 2013
- Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipientsBritish Journal of Clinical Pharmacology, 2011
- Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older childrenPediatric Transplantation, 2010
- Risk Factors Associated With Graft Loss and Patient Survival After Kidney TransplantationTransplantation Proceedings, 2009
- The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony StudyTransplantation, 2009
- Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus ConferenceTherapeutic Drug Monitoring, 2009
- Reduced Exposure to Calcineurin Inhibitors in Renal TransplantationNew England Journal of Medicine, 2007
- Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipientsClinical Pharmacology & Therapeutics, 2004
- Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantationNephrology Dialysis Transplantation, 2001
- EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1993